Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Leerink Swann cut their Q1 2018 EPS estimates for Neurocrine Biosciences in a research note issued to investors on Tuesday. Leerink Swann analyst P. Matteis now forecasts that the company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.07). Leerink Swann has a “Outperform” rating and a $96.00 price target on the stock. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q2 2018 earnings at $0.33 EPS, Q3 2018 earnings at $0.01 EPS, Q4 2018 earnings at $0.17 EPS, FY2018 earnings at $0.30 EPS and FY2019 earnings at $2.53 EPS.
Other equities analysts have also recently issued research reports about the company. Barclays restated an “overweight” rating and set a $100.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, February 14th. BidaskClub upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Citigroup reiterated a “buy” rating and set a $79.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Jefferies Group lifted their price objective on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a report on Friday, January 5th. Finally, Oppenheimer set a $85.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, December 12th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $89.71.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The business had revenue of $94.52 million during the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the prior year, the business posted ($0.51) EPS.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its holdings in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after buying an additional 193 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock valued at $7,380,000 after buying an additional 810 shares in the last quarter. Amalgamated Bank grew its holdings in Neurocrine Biosciences by 5.7% in the 4th quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock valued at $1,357,000 after buying an additional 947 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Neurocrine Biosciences by 25.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock valued at $458,000 after buying an additional 1,200 shares in the last quarter. Finally, Grandfield & Dodd LLC grew its holdings in Neurocrine Biosciences by 24.1% in the 3rd quarter. Grandfield & Dodd LLC now owns 7,610 shares of the company’s stock valued at $466,000 after buying an additional 1,480 shares in the last quarter.
In related news, Director Gary A. Lyons sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $84.67, for a total transaction of $423,350.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Haig P. Bozigian sold 1,625 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total value of $128,570.00. The disclosure for this sale can be found here. Insiders have sold a total of 342,950 shares of company stock worth $27,037,226 in the last ninety days. Insiders own 4.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Brokers Set Expectations for Neurocrine Biosciences, Inc.’s Q1 2018 Earnings (NBIX)” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/22/brokers-set-expectations-for-neurocrine-biosciences-inc-s-q1-2018-earnings-nbix.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.